News
BOVNF
2.980
NaN%
--
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and BioInvent International AB (OtherBOVNF)
TipRanks · 19h ago
BioInvent’s BI-1808 Plus Keytruda Shows Strong Ovarian Cancer Signal in Phase 2a
TipRanks · 1d ago
BioInvent Showcases Promising Ovarian Cancer Antibody BI-1808 in Virtual KOL Event
TipRanks · 2d ago
BioInvent to Showcase Promising BI-1206 Triplet Data in Relapsed NHL at EHA 2026
TipRanks · 05/12 14:31
BioInvent’s BI-1808 Delivers Promising CTCL Responses in Phase 2a Trial
TipRanks · 05/12 14:30
BioInvent AGM Backs New Incentive Plan, Share Issue Mandate and Board Changes
TipRanks · 04/29 16:04
BioInvent Ramps Up Oncology Profile With Dual KOL Events Around ASCO and EHA
TipRanks · 04/29 10:05
BioInvent Narrows Focus on Immuno-Oncology as Q1 Loss Widens and Key Trials Advance
TipRanks · 04/29 06:55
BioInvent to showcase promising BI-1808 and KEYTRUDA combo data in recurrent ovarian cancer at ASCO 2026
TipRanks · 04/21 14:35
BioInvent Narrows Pipeline and Advances Lead Cancer Antibodies in Strategically Focused 2025
TipRanks · 03/31 10:49
BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3
TipRanks · 03/26 15:02
BioInvent Calls 2026 AGM, Sets Governance and Voting Framework
TipRanks · 03/24 07:40
BioInvent Earnings Call: Strong Data, Tight Runway
TipRanks · 03/01 00:19
BioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
TipRanks · 02/26 08:39
BioInvent to Present 2025 Year-End Results in Investor Webcast
TipRanks · 02/26 08:37
BioInvent Taps Industry Heavyweights for Board as Cancer Pipeline Advances
TipRanks · 02/23 09:32
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
TipRanks · 01/05 07:21
BioInvent Steps Up Investor Outreach with Series of 2026 Healthcare Conferences
TipRanks · 12/18/2025 13:45
BioInvent’s BT-001 Clinical Trial Termination: Implications for Investors
TipRanks · 12/14/2025 16:31
BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
TipRanks · 12/08/2025 13:38
More
Webull provides a variety of real-time BOVNF stock news. You can receive the latest news about Bioinvent Intern through multiple platforms. This information may help you make smarter investment decisions.
About BOVNF
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.